AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8642820 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic aspirator at 100% power output
Number of subjects: 6
Study 8642820 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic aspirator in 100% CAVI‐Pulse mode 1
Number of subjects: 6
Study 8642820 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic aspirator in 100% CAVI‐Pulse mode 3
Number of subjects: 6
Study 8642820 — intervention group
Group type: COMPARATOR
Intervention: Conventional electrocautery
Number of subjects: 6
Study 8642820 — intervention group
Group type: EXPERIMENTAL
Intervention: All settings of electrocautery with an ultrasonic aspirator
Number of subjects: 6
Study 8642820 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine and sodium nitroprusside
Number of subjects: 6
Study 8642820 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin
Number of subjects: 6
Study 1632393 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous biphasic shocks
Number of subjects: 33
Study 1632393 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous monophasic shocks
Number of subjects: 33
Study 1632393 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential monophasic shocks
Number of subjects: 33
Study 6084754 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg b.i.d. for 10 days)
Number of subjects: 27
Study 6084754 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 27
Study 3762240 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician/nurse talk
Number of subjects: 0
Study 3762240 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder postcard
Number of subjects: 0
Study 3762240 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder phone call
Number of subjects: 0
Study 3762240 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 29383065 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART Goal Enhanced Debriefing
Number of subjects: 80
Study 29383065 — intervention group
Group type: COMPARATOR
Intervention: Standard Debriefing
Number of subjects: 80
Study 26654244 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 300 ml dose of anthocyanin-rich cherry juice
Number of subjects: 13
Study 26654244 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 100 ml doses of anthocyanin-rich cherry juice
Number of subjects: 13
Study 23845721 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial valve therapy (EBV)
Number of subjects: 416
Study 23845721 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy (control)
Number of subjects: 416
Study 22594100 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling sensation acupuncture
Number of subjects: 29
Study 22594100 — intervention group
Group type: EXPERIMENTAL
Intervention: Shallow acupuncture
Number of subjects: 29
Study 22594100 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 29
Study 22594100 — intervention group
Group type: COMPARATOR
Intervention: Non-acupoint acupuncture
Number of subjects: 29
Study 22594100 — intervention group
Group type: COMPARATOR
Intervention: Deep acupuncture
Number of subjects: 29
Study 20820148 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam 0.05-mcg/kg/min
Number of subjects: 40
Study 20820148 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fenoldopam)
Number of subjects: 40
Study 19127796 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term amoxicillin-clavulanic acid
Number of subjects: 122
Study 19127796 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term penicillin
Number of subjects: 122
Study 19127796 — intervention group
Group type: COMPARATOR
Intervention: Short-term penicillin
Number of subjects: 122
Study 19127796 — intervention group
Group type: COMPARATOR
Intervention: Long-term amoxicillin-clavulanic acid
Number of subjects: 122
Study 17085378 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential oral and transdermal estradiol regimen (2 mg oral micronized 17beta‐estradiol/day or 1.5 mg 17beta‐estradiol gel/day) combined with oral dydrogesterone (10 mg/day, 12 days/month) for 1 year
Number of subjects: 15
Study 12800871 — intervention group
Group type: EXPERIMENTAL
Intervention: Homogenized cow's milk
Number of subjects: 44
Study 12800871 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhomogenized cow's milk
Number of subjects: 44
Study 10805047 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation training session
Number of subjects: 7
Study 10805047 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control day
Number of subjects: 7
Study 8729096 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 1796408 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin intravenously 30,000-40,000 U daily
Number of subjects: 97
Study 1796408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 6823433 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet free from cow's milk
Number of subjects: 66
Study 6823433 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk whey protein
Number of subjects: 66
Study 30613964 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT)
Number of subjects: 480
Study 30613964 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy (CCRT) alone
Number of subjects: 480
Study 28622081 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 18
Study 28622081 — intervention group
Group type: COMPARATOR
Intervention: SHAM
Number of subjects: 18
Study 27315239 — intervention group
Group type: COMPARATOR
Intervention: Yoga program for 60 minutes once a week for 12 weeks.
Number of subjects: 40
Study 24490842 — intervention group
Group type: EXPERIMENTAL
Intervention: 15‐minute script via an iPod leading through visual imagery (cognitive relaxation) or deep breathing exercises (somatic relaxation)
Number of subjects: 97
Study 24490842 — intervention group
Group type: COMPARATOR
Intervention: Control group listened to 15 minutes of ambient nature sounds
Number of subjects: 97
Study 21406956 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation intervention for 2 months, weekly group sessions.
Number of subjects: 114
Study 20408391 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified NIDA Standard Intervention (SI)
Number of subjects: 501
Study 20408391 — intervention group
Group type: EXPERIMENTAL
Intervention: SI + Well Woman Exam (SI+WWE)
Number of subjects: 501
Study 20408391 — intervention group
Group type: EXPERIMENTAL
Intervention: SI + Well Woman Exam + 4 Educational Sessions (SI+WWE+4ES)
Number of subjects: 501
Study 20408391 — intervention group
Group type: COMPARATOR
Intervention: Standard Intervention (SI)
Number of subjects: 501
Study 17684658 — intervention group
Group type: EXPERIMENTAL
Intervention: BTE hearing aids with open molds
Number of subjects: 50
Study 17684658 — intervention group
Group type: COMPARATOR
Intervention: BTE hearing aids with pressure vent molds
Number of subjects: 50
Study 16271337 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (800 mg 3 times daily)
Number of subjects: 68
Study 16271337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 12600812 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (add-on therapy)
Number of subjects: 574
Study 10368798 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin 3.6 mg implant four weekly + placebo tablets daily (Group C)
Number of subjects: 60
Study 10368798 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin 3.6 mg implant four weekly + estradiol valerate 2 mg daily with norethisterone 5 mg from days 21-28 of a 28-day cycle (Group B)
Number of subjects: 60
Study 10368798 — intervention group
Group type: COMPARATOR
Intervention: Placebo implant four weekly + placebo tablets daily (Group A)
Number of subjects: 60
Study 8897354 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,6 benzo‐[alpha]‐pyrone (coumarin 400 mg/day) for six months
Number of subjects: 60
Study 8897354 — intervention group
Group type: COMPARATOR
Intervention: Placebo for six months
Number of subjects: 60
Study 8897354 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat therapy (microwave) plus compression garments for six months
Number of subjects: 60
Study 8897354 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzopyrones for 12 months plus heat treatment for six months
Number of subjects: 60
Study 8897354 — intervention group
Group type: COMPARATOR
Intervention: Heat therapy plus either placebo or benzopyrone
Number of subjects: 60
Study 1509748 — intervention group
Group type: EXPERIMENTAL
Intervention: CEDIA assays
Number of subjects: 0
Study 1509748 — intervention group
Group type: COMPARATOR
Intervention: Fluorescence polarization immunoassay
Number of subjects: 0
Study 1509748 — intervention group
Group type: COMPARATOR
Intervention: HPLC
Number of subjects: 0
Study 6711782 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg buprenorphine pre‐emptively for postoperative pain
Number of subjects: 0
Study 6711782 — intervention group
Group type: COMPARATOR
Intervention: Morphine or placebo
Number of subjects: 0
Study 30662387 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl combined with midazolam
Number of subjects: 44
Study 30662387 — intervention group
Group type: COMPARATOR
Intervention: Midazolam alone (control group)
Number of subjects: 44
Study 30662387 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study 28993346 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate active treatment with intravenous abatacept
Number of subjects: 20
Study 28993346 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment arm
Number of subjects: 20
Study 28993346 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 20
Study 27260839 — intervention group
Group type: EXPERIMENTAL
Intervention: Talactoferrin (TLf) 150 mg/kg every 12 hours for 28 days
Number of subjects: 120
Study 27260839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 27260839 — intervention group
Group type: EXPERIMENTAL
Intervention: Talactoferrin (TLf)
Number of subjects: 120
Study 27260839 — intervention group
Group type: COMPARATOR
Intervention: Talactoferrin (TLf) and Placebo
Number of subjects: 120
Study 24929798 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate or intense supervised exercise training thrice-weekly for 12 weeks
Number of subjects: 37
Study 24929798 — intervention group
Group type: COMPARATOR
Intervention: Control group (DM without neuropathy)
Number of subjects: 37
Study 24929798 — intervention group
Group type: COMPARATOR
Intervention: Control group (DM-PN with neuropathy)
Number of subjects: 37
Study 22532269 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0
Study 22532269 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 0
Study 22532269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20393508 — intervention group
Group type: EXPERIMENTAL
Intervention: HGF plasmid (beperminogene perplasmid, Collategene) injected intramuscularly on days 0 and 28
Number of subjects: 44
Study 20393508 — intervention group
Group type: COMPARATOR
Intervention: Placebo injected intramuscularly on days 0 and 28
Number of subjects: 44
Study 20393508 — intervention group
Group type: EXPERIMENTAL
Intervention: HGF plasmid (beperminogene perplasmid, Collategene) injected intramuscularly
Number of subjects: 44
Study 20393508 — intervention group
Group type: COMPARATOR
Intervention: Placebo injected intramuscularly
Number of subjects: 44
Study 20393508 — intervention group
Group type: EXPERIMENTAL
Intervention: HGF plasmid (beperminogene perplasmid, Collategene)
Number of subjects: 44
Study 18780502 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined in-office cold light bleaching and night-guard vital bleaching (NGVB) system
Number of subjects: 90
Study 18780502 — intervention group
Group type: COMPARATOR
Intervention: In-office cold light bleaching
Number of subjects: 90
Study 18780502 — intervention group
Group type: COMPARATOR
Intervention: Night-guard vital bleaching (NGVB)
Number of subjects: 90
Study 15824494 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labour
Number of subjects: 54
Study 15824494 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 54
Study 12424329 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene supplementation (30 mg of lycopene from tomato oleoresin extract)
Number of subjects: 26
Study 12424329 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (control group)
Number of subjects: 26
Study 10090434 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day grepafloxacin 400 mg once daily
Number of subjects: 389
Study 10090434 — intervention group
Group type: COMPARATOR
Intervention: 10-day grepafloxacin 400 mg once daily
Number of subjects: 389
Study 7788193 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional warming
Number of subjects: 14
Study 7788193 — intervention group
Group type: COMPARATOR
Intervention: Standard management
Number of subjects: 14
Study 2190405 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical Bacillus Calmette-Guérin (BCG)
Number of subjects: 100
Study 2190405 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study 85162 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (60 mg daily) with bromocriptine (mean dose 148 mg daily)
Number of subjects: 17
Study 85162 — intervention group
Group type: COMPARATOR
Intervention: Placebo with bromocriptine (average daily dose 92 mg)
Number of subjects: 17
Study 31642699 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin measured at birth (umbilical cord sample), 48-72 hours, 4 months and 12 months
Number of subjects: 456
Study 31642699 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin measured at 12 months
Number of subjects: 456
Study 31642699 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin measured at 0-3 days of age
Number of subjects: 456
Study 26873098 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BTJ) 250 ml
Number of subjects: 10
Study 26873098 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole beetroot (BF) 300 g
Number of subjects: 10
Study 26873098 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 10
Study 25531167 — intervention group
Group type: EXPERIMENTAL
Intervention: Just-in-time (JIT) training before CPA
Number of subjects: 324
Study 25531167 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time visual feedback (VisF) during CPA
Number of subjects: 324
Study 25531167 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of JIT training and real-time VisF
Number of subjects: 324
Study 25531167 — intervention group
Group type: COMPARATOR
Intervention: Control group (no JIT training and no VisF)
Number of subjects: 324
Study 24021679 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracerebral hemorrhage cases
Number of subjects: 2506
Study 24021679 — intervention group
Group type: COMPARATOR
Intervention: Controls matched by age, race, ethnicity, sex, and metropolitan region
Number of subjects: 2506
Study 24021679 — intervention group
Group type: EXPERIMENTAL
Intervention: Cases with imaging submitted
Number of subjects: 2506
Study 24021679 — intervention group
Group type: EXPERIMENTAL
Intervention: Cases with MRI evaluation
Number of subjects: 2506
Study 21946357 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalbuminuria group (n=96)
Number of subjects: 920
Study 21946357 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalbuminuria group (n=96) in diabetic patients
Number of subjects: 920
Study 19673331 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenmai Injection (SMI) 0.6 mL/kg in 250 mL physiological saline
Number of subjects: 30
Study 19673331 — intervention group
Group type: COMPARATOR
Intervention: Control group received 250 mL physiological saline
Number of subjects: 30
Study 19673331 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenmai Injection (SMI)
Number of subjects: 30
Study 19673331 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 16840747 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg) administered by intravenous infusion at Weeks 0, 2, and 6
Number of subjects: 38
Study 16840747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 14699431 — intervention group
Group type: EXPERIMENTAL
Intervention: Melancholic depression
Number of subjects: 38
Study 14699431 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 38
Study 14699431 — intervention group
Group type: COMPARATOR
Intervention: Melancholic subjects
Number of subjects: 38
Study 11273875 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (MEL) 0.3 mg/kg
Number of subjects: 9
Study 11273875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 11273875 — intervention group
Group type: COMPARATOR
Intervention: Intravenous iron (100 mg of Fe saccharate)
Number of subjects: 9
Study 11273875 — intervention group
Group type: COMPARATOR
Intervention: Recombinant human erythropoietin (rHuEPO 4,000 U)
Number of subjects: 9
Study 9237085 — intervention group
Group type: EXPERIMENTAL
Intervention: Talking privately about stressful events (disclosure group)
Number of subjects: 72
Study 9237085 — intervention group
Group type: COMPARATOR
Intervention: Talking about trivial topics (control group)
Number of subjects: 72
Study 8055403 — intervention group
Group type: EXPERIMENTAL
Intervention: Low income (less than $10,000)
Number of subjects: 2503
Study 8055403 — intervention group
Group type: EXPERIMENTAL
Intervention: Noneconomic factors (low maternal education and family dysfunction)
Number of subjects: 2503
Study 8055403 — intervention group
Group type: COMPARATOR
Intervention: Control group (children with income above $10,000)
Number of subjects: 2503
Study 3057832 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF-HU (P-100) administered at 2 vials/day (8 X 10(6)U of P-100) by intravenous drip infusion for 7 days starting from the 5th day after chemotherapy initiation.
Number of subjects: 261
Study 3057832 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inactive) administered in the same manner as P-100.
Number of subjects: 261
Study 4992682 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenylamine
Number of subjects: 12
Study 4992682 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 12
Study 30883000 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Number of subjects: 0
Study 30883000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28034509 — intervention group
Group type: EXPERIMENTAL
Intervention: MAXCOG intervention (four weekly sessions of individualized cognitive rehabilitation)
Number of subjects: 55
Study 28034509 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 55
Study 28060927 — intervention group
Group type: EXPERIMENTAL
Intervention: FIFA 11+
Number of subjects: 16
Study 28060927 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmoknee
Number of subjects: 16
Study 28060927 — intervention group
Group type: COMPARATOR
Intervention: Dynamic warm-up (DWU)
Number of subjects: 16
Study 24072665 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 200U
Number of subjects: 691
Study 24072665 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 300U
Number of subjects: 691
Study 24072665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 691
Study 21875517 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical spine manipulation
Number of subjects: 18
Study 21875517 — intervention group
Group type: COMPARATOR
Intervention: Thoracic spine manipulation
Number of subjects: 18
Study 19623190 — intervention group
Group type: EXPERIMENTAL
Intervention: Social marketing-based communications intervention
Number of subjects: 42
Study 19623190 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 42
Study 17303070 — intervention group
Group type: EXPERIMENTAL
Intervention: Claustrophobia Scale (CS)
Number of subjects: 287
Study 17303070 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment
Number of subjects: 287
Study 15519775 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 Gy
Number of subjects: 306
Study 15519775 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 Gy
Number of subjects: 306
Study 15519775 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 306
Study 11766459 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased insulin response (4th quartile)
Number of subjects: 184
Study 11766459 — intervention group
Group type: COMPARATOR
Intervention: Control group (2nd and 3rd quartile)
Number of subjects: 184
Study 9710042 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoblast implantation therapy (60 million myoblasts in one tibialis anterior muscle)
Number of subjects: 3
Study 9710042 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine immunosuppression (5 to 10 mg/kg for 1 year)
Number of subjects: 3
Study 7838921 — intervention group
Group type: COMPARATOR
Intervention: 0 mg/kg caffeine
Number of subjects: 20
Study 7838921 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg caffeine
Number of subjects: 20
Study 7838921 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg caffeine
Number of subjects: 20
Study 7838921 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg caffeine
Number of subjects: 20
Study 3414514 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (160 mg/day)
Number of subjects: 18
Study 3414514 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (240 mg/day)
Number of subjects: 18
Study 3414514 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nadolol and diltiazem
Number of subjects: 18
Study 30125790 — intervention group
Group type: EXPERIMENTAL
Intervention: MoodKit (CBT toolkit app)
Number of subjects: 226
Study 30125790 — intervention group
Group type: EXPERIMENTAL
Intervention: MoodPrism (mood tracking app)
Number of subjects: 226
Study 30125790 — intervention group
Group type: EXPERIMENTAL
Intervention: MoodMission (CBT strategy app)
Number of subjects: 226
Study 30125790 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 226